Paromomycin is used to treat acute and chronic intestinal amebiasis (bowel infection caused by a parasite in your stomach or bowels). It is also used with other medicines to help lessen the symptoms of hepatic coma (a complication of liver disease).
The market is majorly driven by the lifestyle changes, leading to gastrointestinal (GI) diseases.
The global Paromomycin (CAS 7542-37-2) market is segregated on the basis of Type as 99% Purity Type, 96% Purity Type, and Others. Based on Application the global Paromomycin (CAS 7542-37-2) market is segmented in Paromomycin Sulfate and Paromomycin Injection.
The global Paromomycin (CAS 7542-37-2) market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Paromomycin (CAS 7542-37-2) market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.
Competitive Rivalry
Pfizer, Kaifeng Pharm, Shanhe Pharm, Changrui Pharm, ERFA Canada, and others are among the major players in the global Paromomycin (CAS 7542-37-2) market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Paromomycin (CAS 7542-37-2) Market has been segmented as below:
Paromomycin (CAS 7542-37-2) Market, By Type
Paromomycin (CAS 7542-37-2) Market, By Application
Paromomycin (CAS 7542-37-2) Market, By Region
Paromomycin (CAS 7542-37-2) Market, By Company
The report covers:
Report Scope:
The global Paromomycin (CAS 7542-37-2) market report scope includes detailed study covering underlying factors influencing the industry trends.
The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.
The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Paromomycin (CAS 7542-37-2) market share. Major industry players with significant revenue share include Pfizer, Kaifeng Pharm, Shanhe Pharm, Changrui Pharm, ERFA Canada, and others.
Reasons to Buy this Report:
Customization
Customized report as per the requirement can be offered with appropriate recommendations.
Below are our New Reports :-
contract pharmaceutical manufacturing market
1. Introduction
1.1 Key Insights
1.2 Report Overview
1.3 Markets Covered
1.4 Stakeholders
2. Research Methodology
2.1 Research Scope
2.2 Market Research Process
2.3 Research Data Analysis
2.4.1 Secondary Research
2.4.2 Primary Research
2.4.3 Models for Estimation
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach – Segmental Market Analysis
2.5.2 Top-Down Approach – Parent Market Analysis
3. Executive Summary
4. Market Overview
4.1 Introduction
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.2 Porter’s Five Force Analysis
5. Paromomycin (CAS 7542-37-2) Market, By Type
5.1 Introduction
5.2 99% Purity Type
5.2.1 Market Overview
5.2.2 Market Size and Forecast
5.3 96% Purity Type
5.3.1 Market Overview
5.3.2 Market Size and Forecast
5.4 Others
5.4.1 Market Overview
5.4.2 Market Size and Forecast
6. Paromomycin (CAS 7542-37-2) Market, By Application
6.1 Introduction
6.2 Paromomycin Sulfate
6.2.1 Market Overview
6.2.2 Market Size and Forecast
6.3 Paromomycin Injection
6.3.1 Market Overview
6.3.2 Market Size and Forecast
7. Paromomycin (CAS 7542-37-2) Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 North America Paromomycin (CAS 7542-37-2), By Type
7.2.2 North America Paromomycin (CAS 7542-37-2), By Application
7.3 Europe
7.3.1 Europe Paromomycin (CAS 7542-37-2), By Type
7.3.2 Europe Paromomycin (CAS 7542-37-2), By Application
7.4 Asia-Pacific
7.4.1 Asia-Pacific Paromomycin (CAS 7542-37-2), By Type
7.4.2 Asia-Pacific Paromomycin (CAS 7542-37-2), By Application
7.5 Rest of the World
7.5.1 Rest of the World Paromomycin (CAS 7542-37-2), By Type
7.5.2 Rest of the World Paromomycin (CAS 7542-37-2), By Application
8. Competitive Insights
8.1 Key Insights
8.2 Company Market Share Analysis
8.3 Strategic Outlook
8.3.1 Mergers & Acquisitions
8.3.2 New Product Development
8.3.3 Portfolio/Production Capacity Expansions
8.3.4 Joint Ventures, Collaborations, Partnerships & Agreements
8.3.5 Others
9. Company Profiles
9.1 Pfizer
9.1.1 Company Overview
9.1.2 Product/Service Landscape
9.1.3 Financial Overview
9.1.4 Recent Developments
9.2 Kaifeng Pharm
9.2.1 Company Overview
9.2.2 Product/Service Landscape
9.2.3 Financial Overview
9.2.4 Recent Developments
9.3 Shanhe Pharm
9.3.1 Company Overview
9.3.2 Product/Service Landscape
9.3.3 Financial Overview
9.3.4 Recent Developments
9.4 Changrui Pharm
9.4.1 Company Overview
9.4.2 Product/Service Landscape
9.4.3 Financial Overview
9.4.4 Recent Developments
9.5 ERFA Canada
9.5.1 Company Overview
9.5.2 Product/Service Landscape
9.5.3 Financial Overview
9.5.4 Recent Developments
The Paromomycin (CAS 7542-37-2) Market has been segmented as below:
Paromomycin (CAS 7542-37-2) Market, By Type
Paromomycin (CAS 7542-37-2) Market, By Application
Paromomycin (CAS 7542-37-2) Market, By Region
Paromomycin (CAS 7542-37-2) Market, By Company
